Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07257876 · 1 trial · 3 indications
DLTs will be evaluated during Cycle 1 (a cycle is 28 days) in Part 1. The number of DLTs will be used to determine the optimal dose
AEs characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0), timing, seriousness, and relationship to study therapy.
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
Tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
| Arm | Type | Description |
|---|---|---|
| Dose Escalation (Part 1) | EXPERIMENTAL | Participants will receive PF-07257876 at escalating dose levels. |
| Dose Expansion (Part 2) - Cohort 1 (NSCLC) | EXPERIMENTAL | Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1. |
| Dose Expansion (Part 2) - Cohort 2 (SCCHN) | EXPERIMENTAL | Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1. |
| Name | Type | Description |
|---|---|---|
| PF-07257876 | BIOLOGICAL | CD47-PDL-1 bispecific antibody |
Inclusion Criteria: * Histological/cytological diagnosis of selected advanced or metastatic tumor * Prior treatment with PD-1 (Programmed cell death 1) or PD-L1 (programmed death-ligand 1) in NSCLC and SCCHN or platinum-based therapy in Ovarian cancer * Confirmed radiographic progression of disease...
Top 20 of 84 competitors
PF-07257876 is an investigational monoclonal antibody being studied for the treatment of non-small cell lung cancer. It is also being evaluated in squamous cell carcinoma of the head and neck and ovarian cancer. The drug is in Phase 1 clinical development and is not yet approved.
PF-07257876 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being studied for its potential to treat certain advanced tumors, including non-small cell lung cancer.
PF-07257876 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials.
PF-07257876 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its safety and tolerability.
PF-07257876 has been studied in a Phase 1 clinical trial with the identifier NCT04881045. This trial, titled 'Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors,' enrolled 29 participants and has been completed.
PF-07257876 is not known to have alternative names. It is a distinct investigational monoclonal antibody developed by Pfizer for the treatment of certain advanced tumors, including non-small cell lung cancer.